Dr. Sorab Gupta
Claim this profileGeisinger Medical Center
Studies Cancer
Studies Squamous Cell Carcinoma
13 reported clinical trials
24 drugs studied
Area of expertise
1Cancer
Stage IV
Stage I
Stage II
2Squamous Cell Carcinoma
Stage IV
Stage I
Stage II
Affiliated Hospitals
Clinical Trials Sorab Gupta is currently running
Pembrolizumab + Radiation vs Chemotherapy + Radiation
for Head and Neck Cancer
This phase II trial studies the effect of pembrolizumab alone compared to the usual approach (chemotherapy \[cisplatin and carboplatin\] plus radiation therapy) after surgery in treating patients with head and neck squamous cell carcinoma that has come back (recurrent) or patients with a second head and neck cancer that is not from metastasis (primary). Radiation therapy uses high energy radiation or protons to kill tumor cells and shrink tumors. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of cancer cells. Carboplatin is also in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab alone after surgery may work better than the usual approach in shrinking recurrent or primary head and neck squamous cell carcinoma.
Recruiting1 award Phase 231 criteria
HN-STAR
for Head and Neck Cancer
People who have been treated for head and neck cancer (HNC survivors) can experience serious consequences from their cancer and its treatment, ongoing risks of new cancers, and other unrelated illnesses. These concerns pose challenges to the provision of comprehensive care to HNC survivors. We created HN-STAR to facilitate and tailor the ongoing care of HNC survivors. Survivors use HN-STAR on a computer or tablet to answer questions about symptoms and health concerns before a routine visit with a cancer care provider. During the clinic visit, the provider uses HN-STAR to see evidence-based recommendations for managing each concern reported by the survivor. The provider and survivor discuss recommendations and select appropriate actions (e.g., testing, referrals, prescriptions, self-management). HN-STAR produces a survivorship care plan that includes all reported concerns and the actions selected in clinic. The survivorship care plan is given to the survivor and the primary care provider. Three months, six months, and nine months later, the survivor uses HN-STAR from home (or clinic) to report their concerns again, and a new survivorship care plan is created each time. Our trial randomizes 20-36 oncology practices from the National Community Oncology Research Program to use HN-STAR or provide usual care to 298-400 recent survivors of head and neck cancer. We hypothesize that survivors in the HN-STAR arm will have greater improvement in patient-centered outcomes (including cancer-related well-being, symptoms, and patient activation) over one year compared to survivors in the usual care arm, measured by surveys at baseline and one year later. We also hypothesize that survivors in the HN-STAR arm will be more likely to receive care that is aligned with evidence-based recommendations during the year of the study than survivors in the usual care arm. Our final aim investigates the implementation of HN-STAR in clinical practice, using interviews and surveys of survivors, providers, and other clinic staff to understand the feasibility, acceptability, appropriateness, and other aspects of providing survivorship care to head and neck cancer survivors.
Recruiting1 award N/A7 criteria
More about Sorab Gupta
Clinical Trial Related3 years of experience running clinical trials · Led 13 trials as a Principal Investigator · 7 Active Clinical TrialsTreatments Sorab Gupta has experience with
- Intensity-Modulated Radiation Therapy
- Cisplatin
- Nivolumab
- Fluorouracil
- Atezolizumab
- Carboplatin
Breakdown of trials Sorab Gupta has run
Cancer
Squamous Cell Carcinoma
Colorectal Cancer
Oropharyngeal Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Sorab Gupta specialize in?
Sorab Gupta focuses on Cancer and Squamous Cell Carcinoma. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage I.
Is Sorab Gupta currently recruiting for clinical trials?
Yes, Sorab Gupta is currently recruiting for 6 clinical trials in Danville Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Sorab Gupta has studied deeply?
Yes, Sorab Gupta has studied treatments such as Intensity-Modulated Radiation Therapy, Cisplatin, Nivolumab.
What is the best way to schedule an appointment with Sorab Gupta?
Apply for one of the trials that Sorab Gupta is conducting.
What is the office address of Sorab Gupta?
The office of Sorab Gupta is located at: Geisinger Medical Center, Danville, Pennsylvania 17822 United States. This is the address for their practice at the Geisinger Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.